Nicox (NICXF) FCF Yield % : -112.35 (As of Apr. 28, 2024)

View and export this data going back to . Start your Free Trial

What is Nicox FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Nicox's Trailing 12-Month Free Cash Flow is $-22.59 Mil, and Market Cap is $20.18 Mil. Therefore, Nicox's FCF Yield % for today is -112.35%.

The historical rank and industry rank for Nicox's FCF Yield % or its related term are showing as below:

NICXF' s FCF Yield % Range Over the Past 10 Years
Min: -164.64 Med: -13.05 Max: -3.4
Current: -112.35

During the past 13 years, the highest FCF Yield % of Nicox was -3.40%. The lowest was -164.64%. And the median was -13.05%.

NICXF's FCF Yield % is ranked worse than
85.48% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs NICXF: -112.35

Nicox's FCF Margin % for the quarter that ended in Jun. 2023 was -302.10%.

Nicox FCF Yield % Historical Data

The historical data trend for Nicox's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox FCF Yield % Chart

Nicox Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Yield %

Get a 7-Day Free Trial

-12.64

-11.56

-2.88

-17.55

-54.91

Nicox Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
FCF Yield %	Get a 7-Day Free Trial															-13.13	-15.52	-28.76	-60.50	-56.84

Competitive Comparison of Nicox's FCF Yield %

For the Biotechnology subindustry, Nicox's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Nicox's FCF Yield % falls into.

Nicox FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Nicox's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-24.541	/	44.6895568
	=	-54.91%

Nicox's annualized FCF Yield % for the quarter that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-9.072	*	2	/	31.9184721
	=	-56.84%

Nicox FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Nicox FCF Yield % Related Terms

Thank you for viewing the detailed overview of Nicox's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox (NICXF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

ALCOX:France NXOA:Germany

Address

2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560

Website

https://www.nicox.com

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines

From GuruFocus

Bausch Health Announces VYZULTA� (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea

By PRNewswire PRNewswire • 02-09-2021